Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on Capital EmployedReturn on Invested CapitalTimes Interest Earned

Lifecore Biomedical, Inc. \De\ (LFCR) Gross Margin (2016 - 2025)

Lifecore Biomedical, Inc. \De\ has reported Gross Margin over the past 16 years, most recently at 38.37% for Q2 2025.

  • For Q2 2025, Gross Margin fell 722.0% year-over-year to 38.37%; the TTM value through May 2025 reached 31.27%, down 136.0%, while the annual FY2025 figure was 31.27%, 136.0% down from the prior year.
  • Gross Margin for Q2 2025 was 38.37% at Lifecore Biomedical, Inc. \De\, up from 28.01% in the prior quarter.
  • Over five years, Gross Margin peaked at 45.59% in Q2 2024 and troughed at 11.12% in Q3 2023.
  • A 5-year average of 31.39% and a median of 32.74% in 2023 define the central range for Gross Margin.
  • Biggest five-year swings in Gross Margin: skyrocketed 2620bps in 2021 and later plummeted -1878bps in 2022.
  • Year by year, Gross Margin stood at 44.76% in 2021, then plummeted by -42bps to 25.97% in 2022, then increased by 27bps to 33.02% in 2023, then grew by 3bps to 34.04% in 2024, then rose by 13bps to 38.37% in 2025.
  • Business Quant data shows Gross Margin for LFCR at 38.37% in Q2 2025, 28.01% in Q1 2025, and 34.04% in Q4 2024.